Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
KPV vs Larazotide
An educational, source-based comparison of KPV and Larazotide — how each peptide works, what it's researched for, and what to know before going deeper.
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Research suggests anti-inflammatory effects via melanocortin pathways and intracellular NF-κB modulation — without the pigmentation effects of full-length α-MSH.
- Inflammatory bowel disease models
- Atopic dermatitis (topical research)
- Mast cell stabilization
- • Not FDA-approved.
- • Most evidence is preclinical.
An octapeptide zonulin antagonist that helps maintain intestinal tight junction integrity, reducing paracellular permeability triggered by gluten in celiac disease.
- Celiac disease (Phase 3 completed)
- Intestinal barrier function ('leaky gut' research)
- Environmental enteropathy
- • Not yet FDA-approved.
- • Investigational; physician oversight required.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| KPV | KPV reduces colonic inflammation in IBD models | Gastroenterology | 2009 | Oral KPV nanoparticles reduced inflammatory markers in mouse colitis. |
| Larazotide | Larazotide acetate for persistent symptoms of celiac disease | Gastroenterology | 2015 | Reduced symptom severity in gluten-exposed celiac patients on gluten-free diet. |
Side-effect & safety grid
- Not FDA-approved.
- Most evidence is preclinical.
- Not yet FDA-approved.
- Investigational; physician oversight required.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
KPV vs Larazotide — Key differences
- Class: KPV is classified as Gastrointestinal · Anti-inflammatory, while Larazotide is Gastrointestinal · Barrier.
- Primary research focus: KPV — inflammatory bowel disease models; Larazotide — celiac disease (phase 3 completed).
- Tag: Gut · Anti-inflammatory vs Gut.